caa a22 4500 469121505 CHVBK 20180323133140.0 cr unu---uuuuu 170328e19920201xx s 000 0 eng 10.1007/BF02246251 doi (NATIONALLICENCE)springer-10.1007/BF02246251 Moclobemide and placebo in mild major depression: a double-blind randomized trial [Elektronische Daten] [E. Ose, P. Holm] Sixty-eight patients participated in this double-blind randomised study with moclobemide versus placebo (35 allocated to moclobemide; 33 to placebo). In terms of mean HAMD total scores, improvement tended to be more pronounced in the moclobemide group at treatment end-point. Efficacy was judged to be ‘very good' or ‘good' in 50% of moclobemide-treated patients and in 27% of placebo-treated patients: in completers only, the difference was more marked (69% versus 33%;P<0.05 Mann-Whitney test). Tolerability was judged to be ‘very good' or ‘good' in 77% of moclobemide-treated patients and in 94% of placebo-treated patients. Adverse events were observed in 31% of patients in the moclobemide group and in 18% of patients in the placebo group. Springer-Verlag, 1992 Moclobemide nationallicence Depression nationallicence Ose E. Sandviken Sykehus, Helleveien 65, N-5035, Sandviken-Bergen, Norway aut Holm P. Roche A/S, International Clinical Research, Industriholmen, DK-2650, Hvidovre, Denmark aut Psychopharmacology Springer-Verlag 106(1992-02-01), S114-S115 0033-3158 106<S114 1992 106 213 https://doi.org/10.1007/BF02246251 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02246251 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ose E. Sandviken Sykehus, Helleveien 65, N-5035, Sandviken-Bergen, Norway aut NATIONALLICENCE 700 1- Holm P. Roche A/S, International Clinical Research, Industriholmen, DK-2650, Hvidovre, Denmark aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 106(1992-02-01), S114-S115 0033-3158 106<S114 1992 106 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer